Sildenafil is used across two primary therapeutic domains that involve specific symptomatic manifestations, including Erectile Dysfunction and the chronic symptomatic relief of Pulmonary Arterial Hypertension.

---

Supporting Functional Consistency in Erectile Dysfunction

This medication is commonly used to help manage the symptoms of erectile dysfunction, which are characterized by the inability to attain or sustain a functionally rigid erection for satisfying sexual activity. This is relevant for managing symptoms that create noticeable functional strain. The therapeutic benefit supports the ability to achieve and maintain functional consistency, which helps ease the associated emotional and physical burden. This provides support that contributes to easing the overall symptom load and may assist with maintaining functional stability during periods of sexual intimacy.

---

Management of Symptoms in Pulmonary Arterial Hypertension

Sildenafil is applied in the chronic management of Pulmonary Arterial Hypertension (PAH), a serious condition that presents with systemic or localized discomfort and heightened physiological activity. It is considered relevant for easing symptom clusters that include shortness of breath during exertion and pronounced fatigue. For these patients, the key benefit is that it may assist with maintaining or supporting physical capacity and exercise tolerance, assisting with maintaining functional stability when symptoms create noticeable physiological strain.

---

Quick Facts

Therapeutic Domain	Symptom Management Role
Erectile Dysfunction	Supports functional consistency during sexual activity.
Pulmonary Arterial Hypertension	Assists with maintaining physical capacity and stability.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use EFFEX Sildenafil?

This section outlines the official population eligibility and non-eligibility rules for Sildenafil, as defined by government regulatory agencies.

Contraindications and Prohibited Use

EFFEX Sildenafil must not be used by patients who are concurrently taking any form of nitrates or nitric oxide donors (e.g., nitroglycerin), or certain Guanylate Cyclase (GC) stimulators (e.g., riociguat). The medicine is also strictly contraindicated in individuals with known hypersensitivity to the active ingredient or a recent history (within the last six months) of stroke or myocardial infarction.

Absolute non-eligibility also applies to patients with severe cardiovascular disorders for whom sexual activity is inadvisable, and those with a history of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in one eye.

Restricted and Age-Related Eligibility

The medicine is not indicated for use in children and adolescents (under 18 years) for the erectile dysfunction (ED) indication, and it is not indicated for use by women for this condition. Caution and conditional eligibility apply to patients with severe renal impairment or hepatic impairment, as official labeling notes potential alterations in drug clearance. Special consideration is also required for patients with anatomical deformation of the penis or conditions predisposing to priapism.

Interactions with other medicines and products

Contraindicated Combinations and Restrictions

The co-administration of Sildenafil with any form of Organic Nitrates or Nitrite Donors (e.g., Nitroglycerin) is formally prohibited. This restriction is due to the severe risk of life-threatening hypotension resulting from the potentiation of vasodilatory effects. Co-administration with the guanylate cyclase stimulator Riociguat is also contraindicated due to the risk of symptomatic hypotension.

---

Metabolic and Exposure Alterations

Sildenafil's clearance is predominantly dependent on the Cytochrome P450 (CYP) 3A4 enzyme system. Co-administration with strong CYP3A4 inhibitors, such as Ritonavir, results in a significant increase in Sildenafil's systemic exposure (AUC and C max). Conversely, co-administration with CYP3A4 inducers, such as Bosentan, significantly decreases Sildenafil plasma levels. In patients with hepatic impairment, higher plasma concentrations of Sildenafil have been observed, which is a population-specific interaction consideration.

---

Pharmacodynamic and Absorption Effects

The co-administration of Sildenafil with Alpha-Blockers (e.g., Doxazosin) may lead to symptomatic hypotension due to additive blood pressure lowering effects. This effect is most likely to occur within four hours of Sildenafil administration. Furthermore, taking the medication with a high-fat meal reduces the rate of absorption, causing a delay in the time to reach maximum plasma concentration. Sildenafil also potentiates the mild hypotensive effect of alcohol (ethanol).

Enzyme Inhibition and cGMP Signal Amplification

Sildenafil functions as a selective competitive inhibitor of the enzyme Phosphodiesterase type 5 ( PDE5). This molecular interaction prevents the rapid hydrolysis of the key secondary messenger, cyclic Guanosine Monophosphate ( cGMP), thereby amplifying and sustaining the cellular signal initiated by Nitric Oxide ( NO).

---

Vascular Tone Modulation and Local Vasodilation

The resulting accumulation of cGMP within the smooth muscle cells activates Protein Kinase G ( PKG), which causes smooth muscle relaxation. This action targets the autonomic regulation of vascular tone, leading to localized vasodilation and a subsequent increase in blood flow within the affected tissue.

---

Mechanistic Dependency and Selectivity

A core aspect of the mechanism is its dependency on the prior release of endogenous NO; the drug only enhances a pre-existing signal and does not initiate the effect independently. While selective for PDE5, the molecule also exhibits lower-level inhibition of PDE6 (in the retina), which results in measurable inhibition of PDE6.

This section provides information regarding the use of Sildenafil, outlining standard dosage and administration guidelines.

Dosage and Frequency

The recommended dosing depends on the medical condition being addressed:

• Erectile Dysfunction (ED): The usual starting dose is 50 mg, taken as needed approximately one hour before sexual activity. The effective dose may range from 25 mg up to a maximum of 100 mg per day. The maximum recommended dosing frequency is once per day.
• Pulmonary Arterial Hypertension (PAH): The recommended dose is 20 mg taken orally three times a day (TID). Doses should be administered approximately 4 to 6 hours apart. An intravenous (IV) dose of 10 mg TID may be used when a patient is temporarily unable to take the oral medication.

Administration Conditions

Condition	Instruction
With Food (ED)	Can be taken with or without food, but a high-fat meal may delay the onset of activity.
Timing (ED)	May be taken anywhere from 30 minutes to 4 hours before sexual activity.
Preparation (Oral Suspension for PAH)	The powder must be reconstituted with water and shaken vigorously for a minimum duration before the initial dose, and shaken briefly before each subsequent use.

Dose Adjustments for Specific Patients

A starting dose of 25 mg for the ED indication should be considered for patients age 65 years and older, those with severe renal impairment (creatinine clearance <30 mL/min), or those with hepatic impairment (e.g., cirrhosis). Patients stable on an alpha-blocker should initiate the ED regimen at the 25 mg dose.

Research Evidence / Overview of Studies for EFFEX Sildenafil

Evidence for use in Erectile Dysfunction (ED)

The evidence base for this medicine was evaluated in numerous research programs. Research has primarily relied on Randomized Controlled Trials (RCTs), where study participants are randomly assigned to receive either the active medicine or a placebo (an inactive pill). These trials examined patient-reported outcomes related to functional consistency.

Studies evaluated in large groups of adult men, including those with conditions associated with functional imbalance, such as diabetes and high blood pressure, as well as men whose symptoms arose after prostate surgery. The findings describe patterns observed in the studies where reported measurements of the ability to engage in sexual activity were compared between the active medicine group and the placebo group.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

Research exploring the medicine's role in conditions marked by functional limitations and physiological strain, such as Pulmonary Arterial Hypertension (PAH), has been conducted through Randomized Controlled Trials (RCTs). These studies examined outcomes related to exercise capacity and clinical status change over defined time intervals. The main outcome research examined was the Six-Minute Walk Distance (6MWD), a standardized assessment used to monitor physiological strain.

Studies reported that the measured changes in exercise capacity (6MWD) were compared against placebo. Research also describes patterns related to the occurrence of clinical worsening events across the treatment groups.

The Current Research Landscape and Uncertainties

The primary RCTs, which form the basis for the initial evidence, were observed in patients over relatively short periods, often ranging from 4 to 16 weeks. Long-term effects are not fully established by continuous, placebo-controlled trials lasting many years.

Findings for certain complex subgroups, such as the pediatric PAH population and specific post-surgical ED patients, appear to require further investigation, as data for certain groups remain insufficient. Regulators have pointed out that evidence is limited for long-term observation in the pediatric population.

Key Studies & References Sildenafil Oral - MedlinePlus Drug Information (General Overview and Indication)

Common questions about ЭФФЕКС Силденафил (FAQ)

Q: How long before sex should I take Sildenafil for ED?

A: Official guidance indicates that Sildenafil is often administered approximately one hour before anticipated sexual activity. The concentration of the drug reaches its highest level in the body, known as maximum plasma concentration, most commonly within 60 minutes after administration on an empty stomach. Official product information notes that the erectile response has been observed for up to four hours, though the response may lessen over that time.

Q: What is the starting dose for Sildenafil for a healthy adult under 65?

A: Regulatory documents state that the usual starting dose for treating erectile dysfunction is 50 mg. The drug is classified as an 'as needed' therapy. The official labeling notes that dose adjustments may be considered for patients with certain conditions, such as severe kidney or liver impairment, or for those who are age 65 and older.

Q: Can women or children take Sildenafil for any condition, like PAH?

A: Official product information notes that Sildenafil is not approved for use in women or children to treat erectile dysfunction. For Pulmonary Arterial Hypertension (PAH), the drug is approved for use in adult men and women. For pregnant or breastfeeding women, the regulatory information specifies that use is only recommended if the potential benefits outweigh the risks. Due to observed mortality risks, one major regulatory body advises against its use in the pediatric PAH population.

Q: How is the intravenous (IV) dose of Sildenafil used in the hospital?

A: The injectable form of Sildenafil is used in a controlled medical environment when a patient is temporarily unable to take the oral tablets. This form is typically administered by a healthcare professional as a 10 mg dose three times per day.

Q: How long does Sildenafil stay in your system or how long does the effect last?

A: The drug's half-life, which describes the time required for half of the substance to be eliminated from the body, is approximately three to four hours. The clinical evidence shows that the erectile response has been observed for up to four hours after dosing, although the effect naturally decreases as the concentration in the body declines.

Q: What are the long-term safety risks or side effects of taking Sildenafil?

A: Official documents and research summaries indicate that the primary clinical trials were conducted over relatively short periods, often lasting from 4 to 16 weeks. Because of this, the long-term effects over many years are not fully established by continuous, placebo-controlled trials. Official safety monitoring continues following market release, and further investigation is still required for specific complex groups, such as the pediatric PAH population.

Q: Does Sildenafil interact with common supplements like St. John's Wort or fish oil?

A: Official regulatory warnings highlight that Sildenafil’s clearance from the body relies on the CYP3A4 enzyme system. Herbal products, such as St. John's Wort, are noted in regulatory information as having the potential to interact with Sildenafil. The regulatory guidance emphasizes the importance of disclosing all supplements and herbal products used, as these agents can affect Sildenafil plasma levels.

Official Storage and Disposal Guidelines

Sildenafil must be stored strictly according to official regulatory documentation to maintain its stability and ensure safety.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C), with permissible excursions.
Protection	Keep in the original container, tightly closed, and protect from moisture.
Child Safety	Must be kept securely out of the reach of children.
Oral Suspension	Discard the liquid form 60 days after reconstitution, even if stored correctly at room temperature.

Disposal Instructions

Dispose of unused Sildenafil according to local laws and regulations for discarding medicines. If a take-back program is unavailable, mix the unused drug with an undesirable substance (such as used coffee grounds or dirt), seal the mixture in a container, and place it in the household trash. Do not flush this medication down the toilet or drain unless specifically instructed by official labeling.